Center for Pharmaceutical Biotechnology & Nanomedicine, 360 Huntington Avenue, 140 The Fenway, Northeastern University, Boston, MA 02115, USA.
Nanomedicine (Lond). 2013 Sep;8(9):1509-28. doi: 10.2217/nnm.13.118.
The use of liposomes for drug delivery began early in the history of pharmaceutical nanocarriers. These nanosized, lipid bilayered vesicles have become popular as drug delivery systems owing to their efficiency, biocompatibility, nonimmunogenicity, enhanced solubility of chemotherapeutic agents and their ability to encapsulate a wide array of drugs. Passive and ligand-mediated active targeting promote tumor specificity with diminished adverse off-target effects. The current field of liposomes focuses on both clinical and diagnostic applications. Recent efforts have concentrated on the development of multifunctional liposomes that target cells and cellular organelles with a single delivery system. This review discusses the recent advances in liposome research in tumor targeting.
脂质体作为药物传递载体的应用始于药物纳米载体的早期历史。这些纳米大小的、双层脂质体囊泡因其高效、生物相容性、非免疫原性、增加化疗药物的溶解度以及能够包裹各种药物的能力，已成为受欢迎的药物传递系统。被动和配体介导的主动靶向作用促进了肿瘤的特异性，减少了不良反应的发生。目前脂质体领域的研究重点是临床和诊断应用。最近的研究集中在开发多功能脂质体上，这些脂质体可以用单一的递药系统靶向细胞和细胞细胞器。本文综述了肿瘤靶向脂质体研究的最新进展。
